Literature DB >> 20109106

Long-term, reversible contraception use among high-risk women treated in a university-based gynecology clinic: comparison between IUD and depo-provera.

Karen L Cropsey1, Catherine Matthews, Samuel Campbel, Sara Ivey, Swati Adawadkar.   

Abstract

BACKGROUND: The study was conducted to compare rates of sexually transmitted diseases (STD) and side effects in a cohort of high-risk women who received either an intrauterine device (IUD) or depo-medroxyprogesterone acetate (DMPA).
METHODS: We performed a retrospective chart review study of women seeking contraception at an innercity resident obstetrics/gynecology clinic. We compared 194 women with IUDs vs. 191 women receiving DMPA. Mean age was 31.9 years, with 75.1% and 69.2% being nonwhite and single, respectively. More white women received the IUD (34.5% vs. 15.0%, p < 0.001), and significantly more single women received DMPA (85.2% vs. 53.9%, p < 0.001).
RESULTS: After controlling for potentially confounding variables, DMPA women were significantly more likely to have a subsequent STD, although this effect disappeared when interaction terms were added to the model. Overall, duration of contraception use and being black were the best predictors of subsequent STD infection. Women who received IUDs were more likely to report side effects but less likely to discontinue use of their birth control (18.8% vs. 67.0%, p < 0.001).
CONCLUSIONS: Although sexual risk factors may have influenced provider prescribing practices in selecting IUD or DMPA, overall rates of STDs and discontinuation rates for IUDs were equivalent or superior to rates for DMPA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20109106     DOI: 10.1089/jwh.2009.1518

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  2 in total

Review 1.  Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections: A Systematic Review and Meta-analysis.

Authors:  Riley J Steiner; Sanjana Pampati; Katherine M Kortsmit; Nicole Liddon; Andrea Swartzendruber; Karen Pazol
Journal:  Am J Prev Med       Date:  2021-09-16       Impact factor: 6.604

2.  Depo Medroxyprogesterone (DMPA) Promotes Papillomavirus Infections but Does Not Accelerate Disease Progression in the Anogenital Tract of a Mouse Model.

Authors:  Jiafen Hu; Sarah A Brendle; Jingwei J Li; Vonn Walter; Nancy M Cladel; Timothy Cooper; Debra A Shearer; Karla K Balogh; Neil D Christensen
Journal:  Viruses       Date:  2022-05-06       Impact factor: 5.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.